New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

viatris limited - midazolam 1 mg/ml;   - solution for injection - 1 mg/ml - active: midazolam 1 mg/ml   excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - conscious sedation before diagnostic or surgical interventions carried out under local anaesthesia (intravenous administration), or in children intranasal or oral administration. long-term sedation in intensive care units (intravenous administration as bolus injection or continuous infusion).

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

viatris limited - midazolam 5 mg/ml;   - solution for injection - 5 mg/ml - active: midazolam 5 mg/ml   excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - conscious sedation before diagnostic or surgical interventions carried out under local anaesthesia (intravenous administration), or in children intranasal or oral administration. long-term sedation in intensive care units (intravenous administration as bolus injection or continuous infusion).

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

viatris limited - darunavir 300mg; darunavir 300mg - film coated tablet - 300 mg - active: darunavir 300mg excipient: colloidal silicon dioxide crospovidone hypromellose magnesium stearate microcrystalline cellulose opadry orange 85f93050 sodium starch glycolate active: darunavir 300mg excipient: colloidal silicon dioxide crospovidone hypromellose magnesium stearate microcrystalline cellulose opadry white 85f18422 purified water   sodium starch glycolate - darunavir viatris (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus-1 (hiv-1) infection in adult patients. darunavir viatris (with low dose ritonavir as a pharmacokinetic enhancer) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (hiv) infection in treatment-experienced paediatric patients aged greater than or equal to 6 years old and weighing at least 40 kg.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

viatris limited - capecitabine 150mg;  ;   - film coated tablet - 150 mg - active: capecitabine 150mg     excipient: croscarmellose sodium hypromellose   iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose purified talc purified water titanium dioxide - capecitabine viatris tablets in combination with docetaxel is indicated for the treatment of patients with locally-advanced or metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. capecitabine viatris tablets as monotherapy is indicated for the treatment of patients with locally-advanced or metastatic breast cancer after failure of both a taxane-containing and anthracycline-containing chemotherapy or in whom taxane-containing and anthracycline-containing therapy are not indicated.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

viatris limited - capecitabine 500mg;  ;   - film coated tablet - 500 mg - active: capecitabine 500mg     excipient: croscarmellose sodium hypromellose   iron oxide red iron oxide yellow lactose magnesium stearate microcrystalline cellulose purified talc purified water titanium dioxide - capecitabine viatris tablets in combination with docetaxel is indicated for the treatment of patients with locally-advanced or metastatic breast cancer after failure of prior anthracycline-containing chemotherapy. capecitabine viatris tablets as monotherapy is indicated for the treatment of patients with locally-advanced or metastatic breast cancer after failure of both a taxane-containing and anthracycline-containing chemotherapy or in whom taxane-containing and anthracycline-containing therapy are not indicated.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

viatris limited - lenalidomide 10mg - capsule - 10 mg - active: lenalidomide 10mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   indigo carmine iron oxide black iron oxide yellow   microcrystalline cellulose sodium stearyl fumarate starch tekprint black sw-9008 titanium dioxide   - multiple myeloma (mm) " the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. " the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. " in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

viatris limited - lenalidomide 15mg - capsule - 15 mg - active: lenalidomide 15mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   microcrystalline cellulose opacode red s-1-15094 sodium stearyl fumarate starch titanium dioxide   - multiple myeloma (mm) " the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. " the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. " in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

viatris limited - lenalidomide 2.5mg - capsule - 2.5 mg - active: lenalidomide 2.5mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   indigo carmine iron oxide yellow microcrystalline cellulose sodium stearyl fumarate starch tekprint black sw-9008 titanium dioxide   - multiple myeloma (mm) " the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. " the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. " in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

viatris limited - lenalidomide 20mg - capsule - 20 mg - active: lenalidomide 20mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   indigo carmine iron oxide yellow microcrystalline cellulose opacode red s-1-15095 sodium stearyl fumarate starch titanium dioxide   - multiple myeloma (mm) " the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. " the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. " in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.

New Zealand - Ingliż - Medsafe (Medicines Safety Authority)

viatris limited - lenalidomide 25mg - capsule - 25 mg - active: lenalidomide 25mg excipient: colloidal silicon dioxide croscarmellose sodium gelatin   microcrystalline cellulose sodium stearyl fumarate starch tekprint black sw-9008 titanium dioxide   - multiple myeloma (mm) " the treatment of patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplantation. " the maintenance treatment of patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation. " in combination with dexamethasone is indicated for the treatment of multiple myeloma patients whose disease has progressed after one therapy.